German radiopharmaceutical firm ITM Isotope Technologies Munich and Navigo Proteins are teaming up to develop a fibroblast activation protein (FAP)-targeted radiopharmaceutical program for the treatment of solid tumors.
Navigo develops optimized scaffold protein-based affinity ligands called Affilin molecules, the companies said. Under the agreement, Navigo's protein engineering platform will be used to develop and select a FAP-targeting Affilin molecule, which will be paired with a therapeutic radioisotope provided by ITM. Following the selection, ITM will have exclusive rights to further develop the radiolabeled FAP-specific Affilin through clinical testing in potentially multiple cancer indications.
The agreement also includes a nonexclusive license for diagnostic use in radioimaging.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
